Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer

This review examines the evolving treatment landscape for KRAS -mutant non–small cell lung cancer (NSCLC), along with the significance of KRAS mutations. The development of KRAS G12C inhibitors, such as sotorasib and adagrasib, has changed the treatment landscape for patients with KRAS -mutant NSCLC, overcoming the long-standing challenge of targeting KRAS . However, acquired resistance remains a major hurdle, along with the need for effective therapies for non-G12C KRAS mutations. Ongoing research into next-generation inhibitors and combination strategies aim to improve the clinical outcomes of KRAS -mutant NSCLC patients.